{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:47Z","timestamp":1791305147199,"version":"4.3.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00892","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T01:06:35Z","timestamp":1568077595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation"],"prefix":"10.3389","volume":"9","author":[{"given":"Andrei","family":"Colita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horia","family":"Bumbea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Croitoru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Orban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia Eugenia","family":"Lipan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana-Gabriela","family":"Craciun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Soare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Ghimici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Manolache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionel","family":"Gelatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Vladareanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Pasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Teodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bbmt.2015.10.015","article-title":"Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning","volume":"22","author":"Brammer","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/bmt.2016.134","article-title":"A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM","volume":"51","author":"Kothari","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41409\u2013018-0349\u20134","article-title":"LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma","volume":"54","author":"Dos Santos","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B7","first-page":"653","article-title":"Classical Hodgkin's Lymphoma","volume-title":"The EBMT Handbook. Hematopoietic Stem CellTransplantation and Cellular Therapies.","author":"Mart\u00ednez","year":"2019"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/bmt.2014.121","article-title":"Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose","volume":"49","author":"dos Santos","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-016-0399-z","article-title":"PET-CT in staging, response evaluation, and surveillance of lymphoma","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Curr Treat Options Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000443469","article-title":"Haploidentical donors: can faster transplantation be life-saving for patients with advanced disease?","volume":"135","author":"Tanase","year":"2016","journal-title":"Acta Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1515\/rjim-2016-0021","article-title":"First successful haploidentical stem cell transplantation in Romania","volume":"54","author":"T\u0103nase","year":"2016","journal-title":"Rom J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1002\/cam4.879","article-title":"Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective","volume":"5","author":"Reid","year":"2016","journal-title":"Cancer Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/2193-1801-2-489","article-title":"Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS","volume":"2","author":"Sharma","year":"2013","journal-title":"Springerplus."},{"key":"B15","first-page":"66","article-title":"Treatment of malignant lymphomas with very-high-dose CVB followed by transplantation of autologous blood stem cells collected after mobilizing chemotherapy","volume":"76","author":"Majolino","year":"1991","journal-title":"Haematologica."},{"key":"B16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1200\/JCO.2003.11.103","article-title":"High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy","volume":"21","author":"Federico","year":"2003","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.seminhematol.2016.05.010","article-title":"Treatment of relapsed and refractory Hodgkin Lymphoma","volume":"53","author":"von Tresckow","year":"2016","journal-title":"Semin Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica."},{"key":"B22","doi-asserted-by":"publisher","first-page":"CD009411","DOI":"10.1016\/j.critrevonc.2014.04.003","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis","volume":"92","author":"Rancea","year":"2014","journal-title":"Crit Rev Oncol Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD009411","DOI":"10.1002\/14651858.CD009411.pub2","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12185-015-1927-5","article-title":"LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy","volume":"103","author":"Khattry","year":"2016","journal-title":"Int J Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hon.956","article-title":"LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre","volume":"29","author":"Pavlu","year":"2011","journal-title":"Hematol Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.3109\/10428194.2013.842989","article-title":"Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma","volume":"55","author":"Scortechini","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/1097-0142(19950315)75:6<1354::AID-CNCR2820750618>3.0.CO;2-M","article-title":"A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma","volume":"75","author":"Chao","year":"1995","journal-title":"Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1083-8791(01)70015-8","article-title":"Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease","volume":"7","author":"Stuart","year":"2001","journal-title":"Biol Blood Marrow Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6002\/ect.2011.0092","article-title":"Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol","volume":"10","author":"Ramzi","year":"2012","journal-title":"Exp Clin Transplant."},{"key":"B30","first-page":"343","article-title":"The diagnostic characteristics of a group of patients with primary gastric lymphoma: macroscopic, histopathological and immunohistochemical aspects","volume":"53","author":"Rotaru","year":"2012","journal-title":"Rom J Morphol Embryol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V122.21.2127.2127","article-title":"Safety and Efficacy Of Lomustine (CCNU) Substituting Carmustine (BCNU) in conditioning for autologous haematopoietic stem cell transplantation in lymphoma. a retrospective analysis of two patient cohorts over a ten year period","volume":"122","author":"Kulkarni","year":"2013","journal-title":"Blood."},{"key":"B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","article-title":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma","volume":"34","author":"Wang","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/1097-0142(19830515)51:10<1814::AID-CNCR2820511010>3.0.CO;2-Y","article-title":"Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia","volume":"51","author":"Cordonnier","year":"1983","journal-title":"Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1200\/JCO.1991.9.10.1871","article-title":"Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease","volume":"9","author":"Reece","year":"1991","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E884","DOI":"10.3390\/jcm8060884","article-title":"Clinical approach to the patient in critical state following immunotherapy and\/or stem cell transplantation: guideline for the on-call physician","volume":"8","author":"Constantinescu","year":"2019","journal-title":"J Clin Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/10408363.2018.1463508","article-title":"Minimal residual disease in chronic lymphocytic leukemia: a consensus paper that presents the clinical impact of the presently available laboratory approaches","volume":"55","author":"Tomuleasa","year":"2018","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","article-title":"Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia","volume":"9","author":"Tomuleasa","year":"2018","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.18632\/oncotarget.23276","article-title":"Protein dysregulation in graft versus host disease","volume":"9","author":"Qian","year":"2017","journal-title":"Oncotarget."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E1175","DOI":"10.3390\/jcm8081175","article-title":"Approach to the adult acute lymphoblastic leukemia patient","volume":"8","author":"Sas","year":"2019","journal-title":"J Clin Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T17:24:51Z","timestamp":1575653091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":40,"alternative-id":["10.3389\/fonc.2019.00892"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00892","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"article-number":"892"}}